Interaction of ACEI antihypertensive agent's administration with the inflammatory status at admission concerning COVID-19 clinical stay outcomes.
Journal
Vascular pharmacology
ISSN: 1879-3649
Titre abrégé: Vascul Pharmacol
Pays: United States
ID NLM: 101130615
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
12
07
2021
revised:
08
12
2021
accepted:
16
01
2022
pubmed:
23
1
2022
medline:
6
4
2022
entrez:
22
1
2022
Statut:
ppublish
Résumé
Interactions between anti-hypertensive agents (ACEI), comorbidities, inflammation, and stress status may impact hospital stay duration in COVID-19 patients. This retrospective study analyzed epidemiological data, comorbidities, metabolic/inflammatory markers, and clinical information from 165 SARS-CoV-2 positive patients. In a multiple linear regression model, an IL-6 higher than 100 mg/L, glucose at admission (baseline levels at the hospital entry), and the interaction between ACEI administration and LDH predicted the days of hospital admission (P < 0.001). In conclusion, hypertensive patients suffering more severe inflammatory condition assessed by LDH levels clinically benefited more and reduced the hospital stay when prescribed ACEI agents than those with lower systemic baseline inflammation at admission.
Identifiants
pubmed: 35065299
pii: S1537-1891(22)00004-0
doi: 10.1016/j.vph.2022.106955
pmc: PMC8769875
pii:
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Antihypertensive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106955Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Références
Immun Ageing. 2020 Aug 14;17:22
pubmed: 32802142
Drugs Aging. 2020 Nov;37(11):779-785
pubmed: 33084001
J Med Virol. 2021 Feb;93(2):1078-1098
pubmed: 32776551
Clin Respir J. 2021 Aug;15(8):904-914
pubmed: 33896114
BMJ Open. 2020 Nov 23;10(11):e042712
pubmed: 33234660
Nutr Hosp. 2021 Oct 13;38(5):1068-1074
pubmed: 34176273
J Int Med Res. 2020 Dec;48(12):300060520979151
pubmed: 33322988
Postgrad Med J. 2022 Jun;98(1160):422-427
pubmed: 33452143
N Engl J Med. 2020 Jun 18;382(25):2431-2440
pubmed: 32356627
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Emerg Microbes Infect. 2020 Dec;9(1):757-760
pubmed: 32228222
Diagnostics (Basel). 2021 Jul 23;11(8):
pubmed: 34441262
Vascul Pharmacol. 2020 Dec;135:106805
pubmed: 32992048
J Med Virol. 2021 Mar;93(3):1665-1671
pubmed: 32946118
Vascul Pharmacol. 2021 Apr;137:106829
pubmed: 33422689
PLoS One. 2017 Feb 2;12(2):e0170811
pubmed: 28151987
SN Compr Clin Med. 2020;2(8):1069-1076
pubmed: 32838147
Hypertens Res. 2020 Jul;43(7):648-654
pubmed: 32341442
Hypertens Res. 2020 Aug;43(8):824-831
pubmed: 32483311
Intern Emerg Med. 2020 Aug;15(5):759-766
pubmed: 32430651
J Clin Med. 2021 Jul 15;10(14):
pubmed: 34300279
Obes Rev. 2020 Nov;21(11):e13128
pubmed: 32845580
Mediators Inflamm. 2020 Nov 25;2020:2914275
pubmed: 33273888
Drugs Ther Perspect. 2020;36(8):347-350
pubmed: 32837189
Acta Virol. 2021;65(1):3-9
pubmed: 33112637
Cardiovasc Res. 2020 Aug 1;116(10):1666-1687
pubmed: 32352535
Minerva Endocrinol (Torino). 2021 Jun;46(2):193-201
pubmed: 33435650